MedKoo Cat#: 528522 | Name: RS-93522

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RS-93522 is a calcium channel antagonist potentially for the treatment of hypertension. RS-93522 had the additional property of inhibiting phosphodiesterase activity in myocardial homogenates with IC50 = 1.6 x 10(-5)M; the potency and efficacy of phosphodiesterase inhibition was similar to that for milrinone in the same system. As expected of Ca channel antagonists, it has a negative inotropic effect on cultured myocardial cells. RS-93522 also has phosphodiesterase inhibitory activity that possibly may potentiate vasodilatation and ameliorate, in part, negative inotropic effects.

Chemical Structure

RS-93522
RS-93522
CAS#104060-12-0

Theoretical Analysis

MedKoo Cat#: 528522

Name: RS-93522

CAS#: 104060-12-0

Chemical Formula: C27H30N2O9

Exact Mass: 526.1951

Molecular Weight: 526.54

Elemental Analysis: C, 61.59; H, 5.74; N, 5.32; O, 27.35

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
RS-93522; RS 93522; RS93522
IUPAC/Chemical Name
3-(4-(2,3-dihydroxypropoxy)phenethyl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
InChi Key
QLNAYPDWIWUVHP-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H30N2O9/c1-16-23(26(32)36-3)25(19-5-4-6-20(13-19)29(34)35)24(17(2)28-16)27(33)37-12-11-18-7-9-22(10-8-18)38-15-21(31)14-30/h4-10,13,21,25,28,30-31H,11-12,14-15H2,1-3H3
SMILES Code
O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OCCC3=CC=C(OCC(O)CO)C=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 526.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Fu RC, Whatley JL, Fleitman JS. Intranasal delivery of RS-93522, a dihydropyridine-type calcium-channel antagonist. Pharm Res. 1991 Jan;8(1):134-5. PubMed PMID: 2014202. 2: Kern JR, Lokensgard DM, Yang TY. Chromatographic separation of the diastereomers of a dihydropyridine-type calcium channel antagonist as the bis-3,5-dinitrobenzoates. J Chromatogr. 1988 Dec 21;457:309-16. PubMed PMID: 3243886. 3: Lidgate DM, Felgner PL, Fleitman JS, Whatley J, Fu RC. In vitro and in vivo studies evaluating a liposome system for drug solubilization. Pharm Res. 1988 Dec;5(12):759-64. PubMed PMID: 3247285. 4: Marsh JD, Dionne MA, Chiu M, Smith TW. A dihydropyridine calcium channel blocker with phosphodiesterase inhibitory activity: effects on cultured vascular smooth muscle and cultured heart cells. J Mol Cell Cardiol. 1988 Dec;20(12):1141-50. PubMed PMID: 2470909.